PL430116A1 - Zastosowanie związku typu triterpenu lupanu do zapobiegania i leczenia choroby Alzheimera i kompozycja farmaceutyczna - Google Patents

Zastosowanie związku typu triterpenu lupanu do zapobiegania i leczenia choroby Alzheimera i kompozycja farmaceutyczna

Info

Publication number
PL430116A1
PL430116A1 PL430116A PL43011619A PL430116A1 PL 430116 A1 PL430116 A1 PL 430116A1 PL 430116 A PL430116 A PL 430116A PL 43011619 A PL43011619 A PL 43011619A PL 430116 A1 PL430116 A1 PL 430116A1
Authority
PL
Poland
Prior art keywords
compound
alzheimer
disease
prevention
treatment
Prior art date
Application number
PL430116A
Other languages
English (en)
Other versions
PL241271B1 (pl
Inventor
Mikołaj TOMULEWICZ
Original Assignee
Instytut Badawczy Innowacyjno Rozwojowy Biotomed Spółka Z Ograniczoną Odpowiedzialnością
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Instytut Badawczy Innowacyjno Rozwojowy Biotomed Spółka Z Ograniczoną Odpowiedzialnością filed Critical Instytut Badawczy Innowacyjno Rozwojowy Biotomed Spółka Z Ograniczoną Odpowiedzialnością
Priority to PL430116A priority Critical patent/PL241271B1/pl
Priority to EP20460023.3A priority patent/EP3744331A1/en
Publication of PL430116A1 publication Critical patent/PL430116A1/pl
Publication of PL241271B1 publication Critical patent/PL241271B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

Przedmiotem wynalazku jest zastosowanie związku typu triterpenów pentacyklicznych wykazującego działanie neuroprotekcyjne i określonego wzorem 1, w którym rodniki R1 są takie same lub różne i są wybrane z grupy zawierającej: -OH, -COOH, -Me, -Et, -Bn, -C?N, -NH2, -C(=O)CH3, -CH2OH do wytwarzania wyrobu medycznego lub leku stosowanego w prewencji i leczeniu choroby Alzheimera, przy czym wytwarzany wyrób medyczny zawiera skuteczną ilość związku. Ponadto, przedmiotem zgłoszenia jest także kompozycja farmaceutyczna, zawierająca co najmniej jeden ze związków określonych wzorem ogólnym 1.
PL430116A 2019-05-31 2019-05-31 Połączenie związku typu triterpenu lupanu do zapobiegania i leczenia choroby Alzheimera PL241271B1 (pl)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PL430116A PL241271B1 (pl) 2019-05-31 2019-05-31 Połączenie związku typu triterpenu lupanu do zapobiegania i leczenia choroby Alzheimera
EP20460023.3A EP3744331A1 (en) 2019-05-31 2020-05-13 Combination of betulin and cyclodextrin for use in the treatment of alzheimer's disease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL430116A PL241271B1 (pl) 2019-05-31 2019-05-31 Połączenie związku typu triterpenu lupanu do zapobiegania i leczenia choroby Alzheimera

Publications (2)

Publication Number Publication Date
PL430116A1 true PL430116A1 (pl) 2020-12-14
PL241271B1 PL241271B1 (pl) 2022-08-29

Family

ID=71016473

Family Applications (1)

Application Number Title Priority Date Filing Date
PL430116A PL241271B1 (pl) 2019-05-31 2019-05-31 Połączenie związku typu triterpenu lupanu do zapobiegania i leczenia choroby Alzheimera

Country Status (2)

Country Link
EP (1) EP3744331A1 (pl)
PL (1) PL241271B1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114848652A (zh) * 2022-05-31 2022-08-05 澳门大学 白桦脂醛在制备用于预防或治疗神经退行性疾病的药物中的应用
EP4574142A1 (en) * 2023-12-23 2025-06-25 Instytut Badawczy Innowacyjno Rozwojowy "Biotomed" Sp. Z O.O. Composition for use in enhancing, boosting, restoring and/or preventing the decline of cognitive functions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102164942B (zh) * 2008-09-19 2017-02-15 生物科技研究有限公司 三萜系化合物及其使用的方法
KR101360143B1 (ko) 2012-09-26 2014-02-11 씨에스아이알 몬소니아속 식물 추출물을 함유하는 치매 예방 또는 치료용 조성물
KR20140101119A (ko) * 2013-02-08 2014-08-19 주식회사 엘컴사이언스 베툴린 또는 이의 약제학적으로 허용되는 염을 포함하는 학습과 기억력 또는 인지기능 개선용 조성물
CN106265793B (zh) 2015-06-08 2019-10-29 深圳海王医药科技研究院有限公司 海洋红树植物老鼠簕提取物在制备治疗老年痴呆症药物中的应用
FR3059236B1 (fr) 2016-11-25 2019-05-17 Plant Advanced Technologies Pat Extraits de plantes du genre tagetes et leurs utilisations
CN108339000B (zh) 2017-01-22 2021-08-03 上海弘医堂生物医药科技有限公司 一种人参属植物提取物及其药物组合物和应用

Also Published As

Publication number Publication date
EP3744331A1 (en) 2020-12-02
PL241271B1 (pl) 2022-08-29

Similar Documents

Publication Publication Date Title
CY1124175T1 (el) Νευροδραστικα στεροειδη 19-nor για μεθοδους θεραπευτικης αντιμετωπισης
ZA202110597B (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
BR112022005660A2 (pt) Inibidores de fxia e método de preparação dos mesmos e uso farmacêutico dos mesmos.
CY1123260T1 (el) Ενα αλας νατριου του ν-((1,2,3,5,6,7-eξaϋδpo-s-inδaken-4-υλ)καρβαμοϋλ)-1-ισοπροπυλ-1η-πυραζολο-3-σουλφοναμιδιου
SA521422143B1 (ar) 15-pgdh مثبط
BR112022003514A2 (pt) Degradadores bifuncionais de brd9 e seus métodos de uso
AR032471A1 (es) Derivado de androstano y solvatos del mismo, su uso para la fabricacion de medicamentos, composiciones farmaceuticas que los comprenden, procesos para preparar tales derivados, intermediarios utiles en la preparacion de tales derivados, procesos para preparar tales intermediarios, y compuestos inter
MX2021011811A (es) Protacs que degradan el receptor de estrogeno.
MA42239B1 (fr) Nouveaux dérivés d'hydroxyester, leur procédé de préparation et compositions pharmaceutiques les contenant
AR053162A1 (es) Compuesto 5 - oxo - pirrolidin sustituido, composicion farmaceutica que lo comprende y su uso para preparar un medicamento para el tratamiento del glaucoma.
MX392270B (es) Oxisteroles sustituidos en c7 y metodos de uso de los mismos.
NO20084328L (no) Nye forbindelser
CN103717571B8 (zh) 9‑氨基甲基取代的四环素类化合物
GB201907558D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
EA202191239A1 (ru) Соединения и их применение для лечения дефицита 1-антитрипсина
MX2020003993A (es) Derivados de bencimidazol y sus usos.
GB202010464D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
PH12017500810A1 (en) Substituted 2,4 diamino-quinoline as new anticancer agents
MX2024009773A (es) Composicion farmaceutica que comprende derivados de difenildiazol y metodos de uso.
PH12020551341A1 (en) 4-methyldihydropyrimidinone compounds and pharmaceutical use thereof
CO2021008962A2 (es) Derivados activos de éster de testosterona, composiciones y usos de los mismos
HRP20190211T1 (hr) Inhibitor proteina za prijenos kolesterilestera (cetp) i farmaceutski pripravci koji sadrže spomenuti inhibitor za primjenu u liječenju ili prevenciji kardiovaskularnih bolesti
KR102248110B9 (ko) IF1 (ATPase inhibitory factor 1)을 유효성분으로 함유하는 항암용 약학 조성물
IL285751A (en) New compounds and their pharmaceutical preparations for the treatment of diseases
JOP20190278A1 (ar) مركبات 5، 6-ثنائية الحلقة مندمجة وتركيبات لعلاج الأمراض الطفيلية